drug
(emtricitabine + tenofovir alafenamide)
Marketedupdated 6mo agoby $GILD GILEAD SCIENCES, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (emtricitabine + tenofovir alafenamide)
- phase4PrEP at a Syringe Services Program
- phase4Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"
- phase3SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
- —Express Testing and Same-day Initiation of PrEP Study
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 20, 2028
~1.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Feb 15, 2033patentUS 8754065*PED
- Feb 15, 2033patentUS 8754065*PED
- Feb 15, 2033patentUS 9296769*PED
- Feb 15, 2033patentUS 9296769*PED
- Aug 15, 2032compositionUS 8754065
- Aug 15, 2032compositionUS 8754065
- Aug 15, 2032compositionUS 9296769
- Aug 15, 2032compositionUS 9296769
FDA exclusivities (3)
- Jan 7, 2029ODE-457Orphan Drug (7y)2.1y
- Jun 20, 2028M-316Method (3y)1.6y
- Jun 20, 2028M-316Method (3y)1.6y
News(6)
- Gilead reveals partial clinical hold on 2 CAR-T cell therapy trialsGilead Sciences announced on its third-quarter earnings call Oct. 29 that the company has placed a partial clinical hold on two studies for the CAR-T cell therapy KITE-753 in diffuse large B-cell l…fiercebiotech · 18d ago
- 5 new drug launches that defied industry expectationsA clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.biospace · 20d ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 3mo ago
- Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mountsHIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.biospace · 3mo ago
- STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patentsA group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences over patents for HIV prevention.stat · 4mo ago
- STAT+: AIDS group sues Trump administration over undisclosed agreement with GileadThe AIDS advocacy group PrEP4All has sued the Trump administration over an undisclosed agreement with Gilead.stat · 6mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that